Adaptive Planning in Bladder Cancer (APPLY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01000129|
Recruitment Status : Unknown
Verified October 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : October 22, 2009
Last Update Posted : October 22, 2009
|Condition or disease||Intervention/treatment||Phase|
|Bladder Cancer||Other: Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan) Other: Cone beam CT acquisition||Phase 2|
This study integrates a novel adaptive planning methodology, Adaptive-Planning Organ LOcalisation (A-POLO), with optimised margins and cone beam CT technology for improving the accuracy of radiotherapy treatment delivery.
The previous study (CCR2873, REC 07/Q0801/13) evaluated the use of cone beam CT in radiotherapy for bladder cancer. A larger than expected number of bladder radiotherapy treatments were seen to have been delivered with some element of geographic miss. Using the novel adaptive planning method these fractions of radiotherapy could have been correctly treated. The feasibility of this method has been proven in the previous study, particularly it has been shown that this method is appropriate and provides a simple solution to the problem. It can be carried out by the radiographers at the treatment unit without adding extra time to the treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Adaptive - Predictive Planning for Hypofractionated Bladder Radiotherapy|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||December 2010|
Other: Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)
- Assessment performed online at the treatment unit & verified offline by additional observer. Primary endpoint is met if there is greater than 75% concordance between the assessment made online & offline.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01000129
|Contact: Dr Robert Huddartfirstname.lastname@example.org|
|Contact: Bernadette Johnsonemail@example.com|
|Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator: Dr Robert Huddart|
|Principal Investigator:||Dr Robert Huddart||Royal Marsden NHS Foundation Trust|